A B S T R A C T The objective of this study was to compare the responsiveness of human subjects to the anabolic effects of human growth hormone (HGH) administered at 8 a.m. or at 11 p.m. Three doses of HGH were used: A, 0.0168 U/kg body weight (BW)"'4 per day; B, 0.0532 U/kg BW"/' per day; C, 0.168 U/kg BW"'4 per day. The effect of each dose on daily balances of N, P, Na, and K and on BW was measured. The subjects were of two groups: (a) seven GH-deficient children, of whom three were deficient in ACTH; and (b) three patients with limb-girdle dystrophy. ACTHdeficient patients in group (a) received exogenous cortisol at 7 a.m. In all 10 subjects, the anabolic effects of dose C, and sometimes of B and A, administered at 11 p.m. were significantly (P < 0.05) greater than when administered at 8 a.m. In these experiments plasma cortisol concentration averaged 3 times greater at 8 a.m. than at 11 p.m.
INTRODUCTION
The clinical value of human growth hormone (HGH) as a growth-promoting and anabolic agent is limited by variability in the responsiveness of human subjects and by the limited supply of hormone available. In 2-wk metabolic balance studies, normal children and adults show little or no anabolic response to doses up to 0.15 U/kg body weight (BW)"4 but generally respond to 0.5 U/kg BW"/' (1-B) . Daily injection of about 0.05-0.15 U/kg BW"'4 (the usual dose in long-term treatment of growth retardation) in short children with normal endogenous GH generally does not accelerate growth (9, 10) . GH deficient children are more responsive; doses between 0.015 and 0.15 U/kg BW"4 usually elicit an acute anabolic response (1) . Replacement treatment with HGH at 0.05-0.15 U/kg BW"' accelerates growth in these individuals (11) (12) (13) (14) , although the growth response is variable and sometimes disappointing (15, 16) .
Adult subjects with myotonic and limb-girdle muscular dystrophies also are more sensitive than normals to the anabolic action of 0.015-0.15 U/kg BW"4 (1, 3) ; the hormone consequently is being evaluated as a possible form of treatment for these types of dystrophy.
HGH at a dose of about 0.5 U/kg BW"4 has been suggested as pharmacologic treatment for patients after burns (17, 18) and for hypoglycemia (19, 20) .
The use of HGH for either replacement or pharmacologic therapy is severely limited by scarcity of the hormone, and by the high threshold dose required for anabolic or growth-promoting effect in most subjects with normal endogenous GH. For these reasons, any method of amplifying the human response to HGH will be valuable.
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The Journal of Clinical Investigation Volume 52 April 1973 One possibility involves timing of the HGH injection. After the exogenous hormone is injected intravenously in human subjects, its rate of disappearance from the serum approximates a single exponential function over the period 0-90 min, with a half-time of 15-50 min (21, 22) . The duration of effect of a single dose, however, is not known. Najjar and Blizzard (16) have compared the growth-promoting effect of (a) a specific dose of HGH once a day, (b) twice the dose every other day, and (c) half the dose twice a day, on the rate of growth of pituitary dwarfs. The three schedules were said to be generally equipotent, but data supporting this conclusion were not presented. In the hypophysectomized rat, however, injection of half a specified dose of bovine GH twice a day gave a greater response than injection of the entire dose once a day in the morning (23) .
Another aspect of timing concerns the diurnal rhythm of endogenous HGH, which is secreted by the adenohypophysis largely during the first 2 h of sleep (24) . Furthermore, secretion of cortisol, which antagonizes the anabolic effect of HGH (25, 26) , shows the opposite rhythm. Although this hormone is secreted episodically (27) , its plasma concentration is greater during the day than at night (28, 29) . Further, this concentration falls to a minimum during slow-wave sleep (27) , when plasma growth hormone concentration rises to a maximum (24) . These relationships suggest that the anabolic effectiveness of exogenous HGH may be influenced by the time of day at which it is injected and also by timing of any exogenous glucocorticoid which the patient may be receiving.
The initial objective of the present study was to compare the responsiveness of human subjects to the anabolic effects of HGH injected at 8 a.m. or 11 p.m. Two types of patient were studied: ' (a) growth-hormonedeficient subjects, age 7-18; (b) adult patients with limb-girdle dystrophy. As indicators of response, we measured increments in daily balances of N, P, Na, and K and in body weight (BW). The results of these ex-1 Previous studies (1, 3) have shown that both categories are 5-10 times more responsive to the anabolic effects of HGH than normal individuals. The minimal effective dose for the anabolic effect of HGH in normals is 0.168-0.532 U/kg BW3/' daily, compared to 0.0532-0.168 U/kg BW3'4 for the patients cited. The supply of HGH available to us was not sufficient to conduct these experiments in normals. * Average ±SE (n = 3).
1 Statistically significant response to HGH (P < 0.05 for the difference in daily elemental balance during experimental and control periods of the metabolic balance study). NS signifies P > 0.05.
periments led to additional studies in hypophysectomized patients receiving exogenous cortisol, wherein the time of injection of HGH was held constant and the time of cortisol administration varied.
METHODS
The clinical data of the subjects are summarized in Table  I . (a) Seven children, age 11-19, deficient in HGH. In four the pituitary gland had been removed because of tumor. In these four, and in an additional one with nonneoplastic pituitary disease, deficiency of HGH was accompanied by deficiency of one or more other. pituitary hormones. Criteria for establishing deficiency of HGH, adrenocorticotropin, thyroid-stimulating hormone, gonadotropins, or antidiuretic hormone were as described before (1) . Replacement doses for these deficiencies were: cortisol, 15-25 mg daily, administered at either 7 a.m. or 10 p.m. as specified; thyroxine, 0.2-0.3 mg daily given at 8 am.; pitressin tannate in oil, 3-5 U intramuscularly at 24-to 72-h intervals. During the time of this study, plasma thyroxine iodine concentration was 3.5-6.4 ,ug/100 ml; urine volume did not exceed 1500 ml/day. Plasma cortisol concentrations are given in Table  II. (b) Three patients with limb-girdle dystrophy. The criteria for this diagnosis are given in reference 3.
The effect of HGH at three doses (0.0168 U/kg BW3/4, dose A; 0.0532 U/kg BW814, dose B; 0.168 U/kg BW3/4, dose C) 2 on balances of N, P, Na, and K and on BW was measured as described before (1-3) . The measurement of these responses to a given dose of HGH required a 17 2For a 50 kg subject these doses represent 0.32, 1.00, and 3.2 U/day, respectively. T and l signify the response was significantly (P < 0.05) increased or decreased, respectively, by separating (a) and (b) by 
RESULTS
Experimental series I: comparison of HGH at 8 a.m. and 11 p.m., plasma cortisol being maximal' at 8 a.m. In the four hypophysectomized cases (4-7) who received exogenous cortisol, the entire dose was given at 7 a.m. In these four cases, and also in the six other subjects not receiving exogenous cortisol, the effect of HGH at dose C, B, and (sometimes) A was compared when the hormone was injected at 8 a.m. and when it was injected at bedtime. The experiments, conducted at 30-to 90-day intervals, are listed chronologically in Table II . Average plasma cortisol levels of the patients in all these experiments were highest at 8 a.m., intermediate at 3 p.m., and lowest at 11 p.m.
19 comparisons in all were made: 9 at dose C, 6 at dose B, and 4 at dose A. In no comparison did HGH at 8 a.m. produce a greater effect than at 11 p.m. (Table  III) . In 8 comparisons, no significant difference in response was found. In the remaining 11 comparisons, ' Among the three times at which plasma cortisol concentration was measured: 8 a.m., 3 p.m., and 11 p.m.
HGH administered at 11 p.m. caused significantly greater anabolic effect at bedtime than HGH given at 8 a.m. In 7 of 9 comparisons, dose C administered at 11 p.m. caused a significantly greater response than when given at 8 a.m. For doses B and A this relationship was evident in 3 of 6 and in 1 of 4 comparisons, respectively. The greater effect of HGH injected at 11 p.m. was usually evident in the retentions of N and P, less often in those of Na and K. The results of series I are summarized in Tables III and IV (30) ; HGH injected at bedtime will promote mobilization of free fatty acids during the fasting hours of the night, while this effect after matinal injection will be inhibited by the diurnal food intake (30) . (c) The anabolic action of HGH, which is opposed by cortisol (25, 26) , may be greater after nocturnal injection because the hormone reaches its target tissues during a period when cortisol concentration in extracellular fluids is low.
That mechanism (c) is at least partly responsible was shown by experiments of series II and III in hypophysectomized patients receiving exogenous cortisol. Whether HGH was administered at 8 a.m. or 11 p.m., its anabolic effect was enhanced by separating the administration of HGH and cortisol in time by 8-10 h, thereby reducing the plasma cortisol concentration to < 5 /g/100 ml at the time of HGH injection.
These findings indicate that the anabolic effect of exogenous HGH is influenced by the plasma cortisol concentration at the time of HGH injection, but they do not rule out possible additional influences (mentioned above) by diurnal variations in food intake and physical activity.
We do not know to what extent these relationships in anabolic response during 7 days of HGH treatment can be extrapolated to growth response during months of treatment, Furthermore, we did not investigate other metabolic effects of HGH, such as reduction in carbohvdrate tolerance, decline in plasma amino acid and urea levels, and increase in plasma concentrations of insulin and free fatty acids. The indicators of response to HGH which were monitored, however, are those acute metabolic events most closely related to growth, viz. the deposition of N, P, and K in protoplasm. Therefore, it seems logical that the influences of timing of HGH and cortisol upon the anabolic response to the former, in short-term studies, may have their counterparts in linear growth response during chronic treatment. The present study thus suggests that the growth response to exogenous HGH by children with isolated GH deficiency will be greater if the hormone is injected at 11 p.m. than at 8 a.m., and in those children who also have ACTH deficiency, if the entire daily dose of cortisol is given at 7 a.m. Similarly, the present data suggest that any long-term anabolic effects of HGH on muscles of patients with limb-girdle dystrophy will be greater if the hormone is injected at 11 p.m. than at 8 a.m. The validity of these predictions, however, will need to be tested in appropriate long-term experiments.
The present study utilized only two periods of the day for administration of cortisol and HGH: 7-8 a.m. and 10-11 p.m. Possibly separation of the two hormones in time by a period smaller than 8-12 h, or some schedule of divided doses, may lead to further enhancement of the anabolic response to HGH.
